LICENSE AGREEMENT AMENDMENT

EX-10.47 18 a2205645zex-10_47.htm EX-10.47

Exhibit 10.47

 

LICENSE AGREEMENT AMENDMENT

 

Inasmuch as NewLink Genetics Corporation of Ames, Iowa, and the Medical College of Georgia Research Institute of Augusta Georgia, have a valid and existing License Agreement related to the use of Indoleamine-2,3-Dioxygenase and its inhibitors in Immuno-regulation [*] dated September 13, 2005;

 

and

 

Inasmuch as the parties agree that the License Agreement contains a provision (Section 4.1) for the acquisition of new, related Improvement Technologies by NewLink arising at MCGRI after the Agreement was signed

and

 

Inasmuch as the NewLink has reviewed a new Improvement Technology [*], and wishes to exercise its option to incorporate this technology into the existing License Agreement technology portfolio under its standard royalty terms and use conditions,

 

It is Agreed:

 

That the parties amend the License Agreement relative to its Exhibit A , such that MCG case [*] is to be included in the technology portfolio for development and commercialization by NewLink, effective the date that the License Fee of [*] is received at MCGRI.

 

This present amendment shall hereby be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.

 

 

MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE

 

 

NEWLINK GENETICS

 

 

 

 

 

 

By

/s/Betty Aldridge

 

 

By:

/s/Nicholas N. Vahanian

Name:

Betty Aldridge

 

Name:

Nicholas N. Vahanian

Title:

Executive Director

 

Title:

Chief Medical and Operations Officer

Date:

4/27/06

 

 

Date: 4/21/06